摘要
目的研究托伐普坦辅助治疗对急性心力衰竭患者的临床疗效。方法选取我院2016年2月至2017年2月收治的急性心力衰竭患者94例为研究对象,采用随机数字法将其分为对照组和观察组,每组47例。对照组患者接受常规抗心衰治疗,在此基础上,观察组患者口服托伐普坦治疗。比较两组患者的临床疗效。结果观察组患者的治疗总有效率为91.49%,高于对照组的63.83%(P<0.05)。治疗后,两组患者的HR、SBP及血清BNP水平降低、24 h尿量增多,且观察组的上述指标均优于对照组(P<0.05)。治疗后,两组患者的LVEF和SV明显升高,且观察组高于对照组(P<0.05)。结论托伐普坦辅助治疗对急性心力衰竭患者的临床疗效显著,可明显改善心脏功能,提高心肌收缩能力,且治疗安全性高,值得在临床推广。
Objective To study the clinical curative effect of tolvaptan adjuvant treatment in patients with acute heartfailure. Methods A total of 94 patients with acute heart failure in our hospital from February 2016 to February 2017 wereselected, and randomly divided into control group and observation group, with 47 cases in each group. The control groupreceived conventional anti heart failure treatment, on this basis, the observation group accepted tolvaptan oral treatment.The curative effects were compared in the two groups. Results The total effective rate of the observation group was 91.49%,which was higher than 63.83% of the control group （P〈0.05）. After treatment, the levels of HR, SBP and serum BNP inboth groups decreased and urine volume increased, and the above indexes in the observation group were better than thecontrol group （P〈0.05）. After treatment, the LVEF and SV significantly increased in both groups, and those of theobservation group were higher than the control group （P〈0.05）. Conclusion Tolvaptan adjuvant therapy has the significanteffect on acute heart failure, which can obviously improve heart function and myocardial contractility, with high safety, it isworthy of clinical promotion.
出处
《临床医学研究与实践》
2018年第2期19-21,共3页
Clinical Research and Practice
